Company intelligence / Profile preview
MicroPharm Limited
- Ownership
- Private
- Employees
- ~51
- Development stage
- Commercial
Overview
MicroPharm develops and manufactures immunotherapeutic products—primarily ovine polyclonal antibody-based anti-toxins—for the treatment of acute life-threatening emergencies such as snakebites. The company currently produces two anti-vemon therapeutics for the European common adder and the West African carpet viper. It has expanded manufacturing capacity to support growth as a leading supplier to Europe and Africa.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Ovine polyclonal antibodies (immunotherapeutics)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MicroPharm Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroPharm Limited.